Summary
The blood lymphocyte population was studied in 23 breast cancer patients treated with adjuvant tamoxifen for 1.5–2 years, and in an equal number of control patients. The size and cellular composition of the blood lymphocyte population, as assessed by monoclonal antibodies directed against various subsets, did not differ between the two patient groups. However, lymphocytes from the tamoxifen-treated patients exhibited a significantly lower NK activity against K562 cells. In contrast, the proliferative response of lymphocytes to ConA was significantly higher. These results indicate that tamoxifen may modulate the immune system.
This is a preview of subscription content, log in via an institution to check access.
References
Baum M, Brinkley DM, Dossett JA: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex adjuvant trial organisation. Lancet i: 836–840, 1985
Ribeiro G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant for operable breast carcinoma — 7 yrs results. Eur J Cancer Clin Oncol 21: 897–900, 1985
Fernandez MO, Alaghband-Zadeh J, Burn JI: Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability to response to endocrine therapy. Clin Oncol 9: 245–250, 1983
Paridaens R, Sylvester RJ, Ferazzi E, Legros N, Leclercq G, heuson JC: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46: 2889–2895, 1980
Rose C, Thorpe SM, Lørben J, Daenfeldt JL, Palshof T, Mouridsen HT: Therapeutic effect of tamoxifen related to estrogen level. In: Henningsen B, Linder F, Steichile C (eds) Endocrine treatment of breast cancer. Springer-Verlag, Berlin-Heidelberg-New York, 1980, pp 134–141
Wittliff JL: Steroid hormone receptors in breast cancer. Cancer 53: 630–643, 1984
Harty JI, Catalona WJ, Gomolka DM: Modification of lymphocyte responsiveness by hormones used in the treatment of urologic malignancies. J Urol 116: 484–488, 1976
Myers MJ, Butler LD, Petersen BH: Estradiol-induced alteration in the immune system. II. Suppression of cellular immunity in the rat is not the result of direct estrogenic action. Immunopharmacol 11: 47–55, 1986
Bøyum A: Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation. Scand J Clin Lab Invest 97: 77–89, 1968
Blomgren H, Glas U, Melén B, Wasserman J: Blood lymphocytes after radiation therapy of mammary carcinoma. Acta Radiol Ther 13: 185–200, 1974
Einhorn S, Blomgren H, Strander H: Interferon and spontaneous cytotoxicity in man. I. Enhancement of spontaneous cytotoxicity of peripheral lymphocytes by human leucocyte interferon. Int J Cancer 22: 405–412, 1978
Lilliehöök B, Blomgren H: Strong stimulation of CBA lymphocytes in the mixed lymphocyte interaction with cells from H2 identical strain C3H. Scand J Lmmunol 3: 627–635, 1974
Sheard CR, Reiley F, Tee DEH, Vergani D, Lowe D, Baum M, Cameron AEP: The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T-cell or NK cell markers. Br J Cancer 54: 705–709, 1986
Joensun H, Toivanen A, Nordman E: Effect of Tamoxifen on immune functions. Cancer Treat Rep 70: 381–382, 1986
Wasserman J, Petrini B, Blomgren H: Radiosensitivity of T-lymphocyte subpopulations. J Clin Lab Immunol 7: 139–140, 1982
Baral E, Blomgren H, Rotstein S, Virving L: Antiestrogen effects on human blood lymphocyte subpopulationsin vitro. J Clin Lab Immunol 17: 33–35, 1985
Mandeville R, Ghali S, Chausseau J-P:In vitro stimulation of human NK-activity by an estrogen antagonist (Tamoxifen). Eur J Cancer Clin Oncol 20: 983–985, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rotstein, S., Blomgren, H., Petrini, B. et al. Influence of adjuvant tamoxifen on blood lymphocytes. Breast Cancer Res Tr 12, 75–79 (1988). https://doi.org/10.1007/BF01805743
Issue Date:
DOI: https://doi.org/10.1007/BF01805743